---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-032017"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:05:32.429253+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026

## Summary
- Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.
- Company has 180 days, until July 27, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive business days.
- If not cured, Tenaya may transfer to Nasdaq Capital Market for second 180-day compliance period, subject to eligibility and application.
- Board approved increase in Inducement Plan shares by 2,161,000 to a total of 3,361,000 shares for new-hire equity grants.
- Inducement Plan amendment effective Jan 26, 2026; awards limited to new employees as material inducement under Nasdaq rules.

## SEC filing metadata
- accession: 0001193125-26-032017
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526032017/0001193125-26-032017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526032017/tnya-20260126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-032017
- JSON: https://secwatch.observer/filing/0001193125-26-032017.json
- Plain text: https://secwatch.observer/filing/0001193125-26-032017.txt

## Source-grounded claims
- claim_id: d98ff67a386d671f57685dbaf24236677cb83b01
  claim: Tenaya Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  evidence_excerpt: January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000119312526032017/0001193125-26-032017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.